

FEDERAL MARITIME COMMISSION**Ocean Transportation Intermediary License Applicants**

Notice is hereby given that the following applicants have filed with the Federal Maritime Commission applications for licenses as Non-Vessel Operating Common Carrier and Ocean Freight Forwarder—Ocean Transportation Intermediaries pursuant to section 19 of the Shipping Act of 1984 as amended (46 U.S.C. app. 1718 and 46 CFR 515).

Persons knowing of any reason why any of the following applicants should not receive a license are requested to contact the Office of Freight Forwarders, Federal Maritime Commission, Washington, D.C. 20573.

Non-Vessel-Operating Common Carrier Ocean Transportation Intermediary Applicants:

Golden Bridge International, Inc., 755 North Nash Street, El Segundo, CA 90245, Officers: Jin Zhao, President, (Qualifying Individual), Cecilia Wong, Secretary

Impex Transport, Inc., 145–34 157th Street, Suite 210, Jamaica, NY 11434, Officer: Daniel Oh, President, (Qualifying Individual)

Vessel Agents, Inc., 434 Chelsea Street, East Boston, MA 02128, Officers: Karen E. Fuller, President, (Qualifying Individual), Gayle E. Fuller, Treasurer

W & L International Express, Inc., 1456 President Street, Glendale Heights, IL 60139, Officer: Long Wang, Officer, (Qualifying Individual)

Non-Vessel-Operating Common Carrier and Ocean Freight Forwarder**Transportation Intermediary Applicants:**

Trans Global Projects, Inc., 2414 Morris Avenue, Union, NJ 07083, Officers: Rainer J. Luerssen, Secretary, (Qualifying Individual), Kaisar Ahmad, President

Districargo, Inc., 8015 N.W. 29th Street, Miami, FL 33122, Officers: Fernando Cobo, Treasurer, (Qualifying Individual), Astrid Flaherty, President

Ocean Freight Forwarders—Ocean Transportation Intermediary Applicants:

Cargoland Air & Ocean Cargo, Inc., 1790 N.W. 96 Avenue, Miami, FL 33172, Officer: Susana Olmo, President

Dated: February 11, 2000.

Bryant L. VanBrakle,
Secretary.

[FR Doc. 00–3678 Filed 2–15–00; 8:45 am]

BILLING CODE 6730–01–P

FEDERAL RESERVE SYSTEM**Change in Bank Control Notices; Acquisitions of Shares of Banks or Bank Holding Companies**

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than March 2, 2000.

A. Federal Reserve Bank of Atlanta
(Lois Berthaume, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303–2713:

1. *FMB, Ltd.* (General Partner), Monticello, Florida; F.W. Carraway, Jr. (General Partner), Sopchoppy, Florida; F. Wilson Carraway, III (General and Limited Partner), Thomasville, Georgia; Edward H. Carraway, (General and Limited Partner), Winter Springs, Florida; F.W. Carraway, Jr., (Limited Partner), Sopchoppy, Florida; F.W. Carraway, Jr. Grantor Retained Annuity Trust (Limited Partner), Sopchoppy, Florida; Elizabeth Carraway Neilson (Limited Partner), Monticello, Florida; Caroline Carraway Sutton (Limited Partner), Monticello, Florida; and Rena Katherine Carraway (Limited Partner), Monticello, Florida, to retain voting shares of FMB Banking Corporation, Monticello, Florida, thereby indirectly retain voting shares of Farmers & Merchants Bank, Monticello, Florida.

B. Federal Reserve Bank of Dallas
(W. Arthur Tribble, Vice President) 2200 North Pearl Street, Dallas, Texas 75201–2272:

1. *Wayne and Pearlie Wagner*, Round Top, Texas; to acquire additional voting shares of Round Top Bancshares, Inc., Round Top, Texas, and thereby indirectly acquire voting shares of Round Top State Bank, Round Top, Texas.

Board of Governors of the Federal Reserve System, February 10, 2000.

Robert deV. Frierson,
Associate Secretary of the Board.

[FR Doc. 00–3599 Filed 2–15–00; 8:45 am]

BILLING CODE 6210–01–P

FEDERAL RESERVE SYSTEM**Notice of Proposals To Engage in Permissible Nonbanking Activities or To Acquire Companies That Are Engaged in Permissible Nonbanking Activities**

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffcic.gov/nic/.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 2, 2000.

A. Federal Reserve Bank of Chicago
(Phillip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690–1414:

1. Republic Bancorp Co., Orland Park, Illinois, to engage *de novo* through its subsidiary, Republic Bancorp Co., Orland Park, Illinois, in loan participations, pursuant to § 225.28(b)(1) of Regulation Y.

Board of Governors of the Federal Reserve System, February 10, 2000.

Robert deV. Frierson,
Associate Secretary of the Board.

[FR Doc. 00–3600 Filed 2–15–00; 8:45 am]

BILLING CODE 6210–01–P

FEDERAL RESERVE SYSTEM**Sunshine Act Meeting**

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 11 a.m., Tuesday, February 22, 2000.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION:
Lynn S. Fox, Assistant to the Board; 202-452-3204.

SUPPLEMENTARY INFORMATION: You may call 202-452-3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at <http://www.federalreserve.gov> for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: February 11, 2000.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 00-3781 Filed 2-14-00; 10:51 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute: Development of Idiotype Tumor Vaccines for Treatment of B-Cell Lymphoma

An Opportunity for a Cooperative Research and Development Agreement (CRADA) is available for collaboration with the NCI Intramural Division of Clinical Sciences for the support of Phase III clinical trials evaluating the efficacy of a protein-based immunoglobulin idiotype vaccine in the treatment of low-grade follicular B-cell lymphoma.

AGENCY: National Institutes of Health, PHS, DHHS.

ACTION: Notice of opportunities for Cooperative Research and Development Agreements.

SUMMARY: Pursuant to the Federal Technology Transfer Act of 1986 (FTTA, 15 U.S.C. § 3710; Executive Order 12591 of April 10, 1987 as amended by the National Technology Transfer and Advancement Act of 1995), the National Cancer Institute (NCI) of the National Institutes of Health (NIH) of the Public

Health Service (PHS) of the Department of Health and Human Services (DHHS) seeks a Cooperative Research and Development Agreement (CRADA) with a pharmaceutical or biotechnology company. Any CRADA for development of this technology that includes support for vaccine production, monitoring of Phase III clinical trials and data analysis, or any combination of the above will be considered. The CRADA would have an expected duration of five (5) to seven (7) years. The goals of the CRADA will include the rapid publication of research results and timely commercialization of products, diagnostics and treatments that result from the research. The CRADA Collaborators will have an option to negotiate the terms of an exclusive or nonexclusive commercialization license to subject inventions arising under the CRADA.

ADDRESSES: Proposals and questions about this CRADA opportunity may be addressed to Dr. Karen Muszynski, Technology Development & Commercialization Branch, National Cancer Institute—Frederick Cancer Research and Development Center, Fairview Center, 1003 West Seventh Street, Room 502, Frederick, MD 20852, Telephone: (301) 846-5222; Facsimile: (301) 846-6820.

EFFECTIVE DATE: Organizations must submit a proposal summary preferably one page or less, to NCI within 90 days from date of this publication. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial discussions will have established sufficient mutual interest.

SUPPLEMENTARY INFORMATION:

Technology Available

The National Cancer Institute (NCI) of the National Institutes of Health (NIH) has initiated an FDA-approved, multi-institutional Phase III clinical trial of protein-based immunoglobulin idiotype vaccines for the treatment of low-grade follicular B-cell lymphoma. B-cell tumors are composed of clonally-expanded cells synthesizing a single antibody molecule containing unique variable regions known as idiotypic determinants. The idiotypic determinants of B-cell derived tumors comprise tumor-specific antigens that can serve as a target for immunotherapy. The NCI has previously conducted Phase I and Phase II clinical trials to determine if therapeutically significant immune responses against an autologous, idiotype immunoglobulin protein can be induced in B-cell lymphoma patients (Nature Medicine

5:1171-1177, Oct 1999). Based on results from these studies, the Clinical Research Branch of the NCI has initiated a definitive multi-center Phase III clinical trial of idiotype-specific vaccines for the treatment of low-grade follicular B-cell lymphoma. The NCI, in accordance with the regulations governing the transfer of agents which the Government has taken an active role in developing (37 CFR 404.8), is seeking a pharmaceutical or biotechnology company which can develop these vaccines to a commercially available status to meet the needs of the public and with the best terms for the government.

The NCI specifically seeks a collaborator to support vaccine production and clinical monitoring of the NCI-sponsored Phase III clinical trials in anticipation of the successful commercialization of this technology. Since idiotypic determinants are tumor-specific, the vaccines must be custom-made for each patient. The selected sponsor will collaborate in the development and production of GMP certifiable idiotype vaccines for the treatment of follicular B-cell lymphomas to be used in the Phase III clinical trials leading to a New Drug Application or Biological License Application for a new anti-cancer therapy in anticipation of the successful commercialization of this product. A specific goal of this CRADA will be development of the processes required for large-scale GMP vaccine production and the provision of adequate numbers of GMP produced and formulated idiotype vaccines as needed to complete the clinical development of this agent for the treatment of follicular B-cell lymphoma. The collaborator will be selected based on their ability to provide specific expertise in conversion to GMP vaccine production; experience in preclinical and clinical drug development; experience in the monitoring, evaluation and interpretation of data from investigational agent clinical studies under an IND; and experience in the successful commercialization, marketing and distribution of new cancer therapy products.

The role of the National Cancer Institute in this CRADA may include, but not be limited to:

1. Providing intellectual, scientific, and technical expertise and experience related to the development of idiotype vaccines.
2. Conducting a Phase III clinical trial to evaluate the therapeutic efficacy of idiotype vaccines in association with GM-CSF.
3. Providing scientific and technical expertise in immunological and